Journal / Research
Digital therapeutics and pharmaceutical collaboration
Koa Health announced a collaboration with Janssen to research the use of digital cognitive behavioural therapy for treatment-resistant major depressive disorder patients.
An under-explored combination
Bringing digital therapeutics and pharmaceutical solutions together is still largely uncharted territory. Most of the attention in digital health has gone either to standalone apps and platforms, or to pharmacological research, but not to what happens at the intersection of the two.
For patients who do not respond to existing treatments, that intersection may be exactly where the most useful answers are. Treatment-resistant depression, in particular, is a condition where a combined approach — structured digital therapy alongside medication management — has real potential.
What this kind of collaboration requires
Digital therapeutics and pharmaceutical organisations operate with very different development timelines, regulatory frameworks, and definitions of evidence. Making a collaboration like this work means being honest about those differences and designing the partnership accordingly.
It also means being rigorous about what is claimed. Digital CBT is not a substitute for pharmacological treatment, and pharmaceutical options are not a substitute for structured psychological support. The value is in the combination — and claiming more than the evidence supports damages credibility for everyone in the field.
A direction worth pursuing
The collaboration with Janssen was an early-stage research partnership, not a finished product. But it pointed in a direction that the sector needs to move: towards integrated, evidence-based approaches to mental health care that combine the best of both worlds.
